

CRISPR, Gene Therapies, and Cure Pricing Conundrums
Genetically edited humans are already here. Gene editing has massive implications for treating chronic illnesses and even the food we eat. So what does this mean for your investments and, y'know, possibly humanity? Ricky Mulvey talks with Motley Fool Advisor Karl Thiel about: - How CRISPR works - Some of the…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like Motley Fool Hidden Gems Investing →
Moderna's Cancer Vaccine Breakthrough & Why Uber Could Win the Robotaxi War

Cathie Wood: How to Invest in a World Moving This Fast

Netflix Shares Drop After Earnings, and the Top Biotech Analyst Dissects the Race for a COVID Cure

The Weight-Loss Drug Boom Hits Its Middle Age: What the GLP-1 Economy Means for Your Portfolio
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.


